home / stock / khtrf / khtrf news

KHTRF News and Press, Knight Therapeutics Inc From 08/04/25

Stock Information
Company Name: Knight Therapeutics Inc
Stock Symbol: KHTRF
Market: OTC
Website: gud-knight.com
Menu
KHTRF KHTRF Quote KHTRF Short KHTRF News KHTRF Articles KHTRF Message Board
Get KHTRF Alerts

News, Short Squeeze, Breakout and More Instantly...
KHTRF - Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America

MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has expanded its existing relationship and amended its agreement with Incyte Biosciences International Sàrl, the Swiss...
KHTRF - Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call

MONTREAL, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2025 financial results on Thursday, August 7, 2025 prior to market opening. Following the release, Kn...

KHTRF - Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regula...

KHTRF - Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for CREXONT ® has been accepted for review by Health Canada. CREXONT ® ...
KHTRF - Knight Therapeutics Announces Closing of Previously Announced Acquisition of Paladin

MONTREAL, June 17, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has completed the acquisition of the Paladin business, under the terms of the definitive Asset Purchase Agreement (“A...

KHTRF - Knight Closes US$50 Million Revolving Credit Facility with NBC

MONTREAL, June 17, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has entered into a revolving credit facility (“the Credit Facility”), with Nati...

KHTRF - Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo's Canadian Portfolio

MONTREAL and MARLBOROUGH, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma America Inc. (“SMPA”) announced today that Knight and SMPA’s affiliates have entere...
KHTRF - Knight to Present at the 2025 RBC Capital Markets Global Healthcare Conference in New York City

MONTREAL, May 13, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:  GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2025 RBC Capit...

KHTRF - Knight Therapeutics Inc. (KHTRF) Q1 2025 Earnings Call Transcript

2025-05-11 03:30:45 ET Knight Therapeutics Inc. (KHTRF) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Samira Sakhia – President and Chief Executive Officer Arvind Utchanah – Chief Financial Officer Conference Call Pa...

KHTRF - Knight Therapeutics reports Q1 results

2025-05-08 09:30:03 ET More on Knight Therapeutics Knight Therapeutics Inc. (KHTRF) Q4 2024 Earnings Call Transcript Historical earnings data for Knight Therapeutics Financial information for Knight Therapeutics Read the full article on Seeking Alpha ...
Previous 10 Next 10